Correlation Between DiaMedica Therapeutics and Actinium Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both DiaMedica Therapeutics and Actinium Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DiaMedica Therapeutics and Actinium Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between DiaMedica Therapeutics and Actinium Pharmaceuticals, you can compare the effects of market volatilities on DiaMedica Therapeutics and Actinium Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DiaMedica Therapeutics with a short position of Actinium Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of DiaMedica Therapeutics and Actinium Pharmaceuticals.

Diversification Opportunities for DiaMedica Therapeutics and Actinium Pharmaceuticals

-0.68
  Correlation Coefficient

Excellent diversification

The 3 months correlation between DiaMedica and Actinium is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding DiaMedica Therapeutics and Actinium Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Actinium Pharmaceuticals and DiaMedica Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DiaMedica Therapeutics are associated (or correlated) with Actinium Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Actinium Pharmaceuticals has no effect on the direction of DiaMedica Therapeutics i.e., DiaMedica Therapeutics and Actinium Pharmaceuticals go up and down completely randomly.

Pair Corralation between DiaMedica Therapeutics and Actinium Pharmaceuticals

Given the investment horizon of 90 days DiaMedica Therapeutics is expected to generate 0.76 times more return on investment than Actinium Pharmaceuticals. However, DiaMedica Therapeutics is 1.32 times less risky than Actinium Pharmaceuticals. It trades about 0.1 of its potential returns per unit of risk. Actinium Pharmaceuticals is currently generating about -0.12 per unit of risk. If you would invest  429.00  in DiaMedica Therapeutics on September 12, 2024 and sell it today you would earn a total of  87.00  from holding DiaMedica Therapeutics or generate 20.28% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

DiaMedica Therapeutics  vs.  Actinium Pharmaceuticals

 Performance 
       Timeline  
DiaMedica Therapeutics 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.
Actinium Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Actinium Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

DiaMedica Therapeutics and Actinium Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with DiaMedica Therapeutics and Actinium Pharmaceuticals

The main advantage of trading using opposite DiaMedica Therapeutics and Actinium Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DiaMedica Therapeutics position performs unexpectedly, Actinium Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actinium Pharmaceuticals will offset losses from the drop in Actinium Pharmaceuticals' long position.
The idea behind DiaMedica Therapeutics and Actinium Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.